The role of intraperitoneal therapy in advanced ovarian cancer

ONCOLOGY

Volumn 21, Issue 2, 2007, Pages 227-232

  Hess, Lisa M ^a   Alberts, David S ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; MITOXANTRONE; PACLITAXEL;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DECISION MAKING; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PRACTICE GUIDELINE; REVIEW; STANDARD; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DECISION MAKING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33847179097     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006.
2. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996.
3. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001.
4. National Cancer Institute: NCI clinical announcement on intraperitoneal therapy for ovarian cancer. Posted January 4, 2006. Available at www.cancer.gov/clinicaltrials/developments/IPchemo-digest. Accessed January 11, 2007.
5. Alberts DS, Markman, M, Muggia F, et al: Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancers. Gynecol Oncol 103:783-792, 2006.
6. Armstrong DK, Brady MF: Intraperitoneal therapy for ovarian cancer: A treatment ready for prime time. J Clin Oncol 24:4531-4533, 2006.
7. Bankhead C: Intraperitoneal therapy for advanced ovarian cancer: Will it become standard care? J Natl Cancer Inst 98:510-512, 2006.
8. de Castro G, Jr., Snitcovsky IM, Federico MH: Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med 354:1641-1643 (incl author reply), 2006.
9. Ozols RF, Bookman MA, Young RC: Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med 354:1641-1643 (incl author reply), 2006.
10. Senior K: Intraperitoneal treatment lengthens survival in ovarian cancer. Lancet Oncol 7:107, 2006.
11. Jaaback K, Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006(1):CD005340.
12. Markman M, Walker JL: Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-994, 2006.
13. Provencher DM: [Intraperitoneal chemotherapy for ovarian cancer: A complex strategy but what an exciting avenue!]. Bull Cancer 93:959-960, 2006.
14. Trimble EL, Alvarez RD: Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 103(2 suppl 1):S18-S19, 2006.
15. Trimble EL, Christian MC: Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 100:3-4, 2006.
16. Cannistra SA: Intraperitoneal chemotherapy comes of age. N Engl J Med 354:77-79, 2006.
17. Walker JL, Armstrong DK, Huang HQ, et al: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol 100:27-32, 2006.
18. Wenzel LB, Huang H, Armstrong D, et al: Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (abstract 5026). Proc Am Soc Clin Oncol 23:454, 2004.
19. Gynecologic Oncology Group: IP chemotherapy: Educational materials. Available at www.gog.org/ipchemoed/ipchemoed.html. Accessed January 12, 2007.
20. Southwest Oncology Group: Southwest Oncology Group contributes to new NCI recommendation for treating advanced ovarian cancer. Issued January 6, 2006. Available at http://swog.org/Visitors/Download/Clinical%20Trials/ Advanced_Ovarian_Cancer.pdf. Accessed January 12, 2007.
21. Alberts DS (guest ed): Intraperitoneal chemotherapy: Changing the paradigm for the management of ovarian cancer. Semin Oncol 33(6 suppl 12):51-52, 2007.
22. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003.
23. Hess LM, Benham-Hutchins M, Herzog TJ, et al: A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17(1), 2007.
24. Alberts DS, Markman M, Armstrong D, et al: Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! J Clin Oncol 20:3944-3946, 2002.
25. Cassileth BR, Zupkis RV, Sutton-Smith K, et al: Information and participation preferences among cancer patients. Ann Intern Med 92:832-836, 1980.
26. Kaplan SH, Greenfield S, Ware JE Jr: Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 27(3 suppl):S110-S127, 1989.
27. Morris J, Ingham R: Choice of surgery for early breast cancer: Psychosocial considerations. Soc Sci Med 27:1257-1262, 1988.
28. Morris J, Royle GT: Offering patients a choice of surgery for early breast cancer: A reduction in anxiety and depression in patients and their husbands. Soc Sci Med 26:583-585, 1988.
29. Speedling EJ, Rose DN: Building an effective doctor-patient relationship: From patient satisfaction to patient participation. Soc Sci Med 21:115-120, 1985.
30. Benbassat J, Pilpel D, Tidhar M: Patients' preferences for participation in clinical decision making: A review of published surveys. Behav Med 24:81-88, 1998.
31. Quill TE, Cassel CK: Nonabandonment: A central obligation for physicians. Ann Intern Med 122:368-374, 1995.
32. Gattellari M, Butow PN, Tattersall MH: Sharing decisions in cancer care. Soc Sci Med 52:1865-1878, 2001.
33. Los G, Mutsaers PH, van der Vijgh WJ, et al: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 49:3380-3384, 1989.
34. Francis P, Rowinsky E, Schneider J, et al: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961-2967, 1995.
35. Markman M, Brady MF, Spirtos NM, et al: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study. J Clin Oncol 16:2620-2624, 1998.
36. Howell SB, Pfeifle CL, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851, 1982.
37. Dedrick RL, Myers CE, Bungay PM, et al: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11, 1978.
38. Markman M, Hakes T, Reichman B, et al: Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. J Clin Oncol 9:978-982, 1991.
39. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal Taxol: A Gynecoloic Oncology Group study. J Clin Oncol 10:1485-1491, 1992.
40. Frasci G, Tortoriello A, Facchini G, et al: Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. Gynecol Oncol 50:60-67, 1993.
41. Markman M, George M, Hakes T, et al: Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8:146-150, 1990.
42. Deppe G, Malviya VK, Boike G, et al: Intraperitoneal doxonibicin in combination with systemic cisplatinum and cyclophosphamide in the treatment of stage III ovarian cancer. Eur J Gynaecol Oncol 12:93-97, 1991.
43. Markman M, Howell SB, Lucas WE, et al: Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxonibicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 2:1321-1326, 1984.
44. Malmstrom H, Larsson D, Simonsen E: Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol 39:289-294, 1990.
45. DeGregorio MW, Lum BL, Holleran WM, et al: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18:235-238, 1986.
46. McVie JG, ten Bokkel Huinink W, Dubbelman R, et al: Phase I study and pharmacokinetics of intraperitoneal carboplatin. Cancer Treat Rev 12(suppl A):35-41, 1985.
47. Esposito M, Campora E, Repetto M, et al: Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer. Oncology 45:69-73, 1988.
48. Canal P, de Forni M, Chatelut E, et al: Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate. Acta Med Austriaca 16:84-86, 1989.
49. Repetto L, Chiara S, Guido T, et al: Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study. Anticancer Res 11:1641-1643, 1991.
50. Fujiwara K, Sakuragi N, Suzuki S, et al: First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: Results of long-term follow-up. Gynecol Oncol 90:637-643, 2003.
51. Malmstrom H, Simonsen E, Westberg R: A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 52:20-25, 1994.
52. Markman M, Jones W, Lewis JL Jr, et al: Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. J Cancer Res Clin Oncol 118:163-165, 1992.
53. Barakat RR, Sabbatini P, Bhaskaran D, et al: Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up. J Clin Oncol 20:694-698, 2002.
54. Howell SB, Zimm S, Markman M, et al: Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607-1612, 1987.
55. Markman M, Reichman B, Hakes T, et al: Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479-1484, 1992.
56. Markman M, Reichman B, Hakes T, et al: Salvage intraperitoneal therapy of small-volume residual ovarian cancer: Impact of pre-treatment finding of peritoneal carcinomatosis on the surgical complete response rate. J Cancer Res Clin Oncol 118:235-237, 1992.
57. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991.